Statistics for Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Total visits
| views | |
|---|---|
| Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. | 30 |
Total visits per month
| views | |
|---|---|
| March 2024 | 0 |
| April 2024 | 0 |
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
File Visits
| views | |
|---|---|
| Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cel.pdf | 18 |